-
4 days ago | 
medscape.com | Lucy Hicks
The American College of Rheumatology (ACR) has released a summary of a guideline with updated recommendations for the treatment of systemic lupus erythematosus (SLE). The previous guideline for managing SLE in adults was published in 1999, said Lisa R. Sammaritano, MD, of the Hospital for Special Surgery in New York City, who led the project.
-
4 days ago | 
medscape.com | Lucy Hicks
Patients taking the new class of weight-loss drugs do not need to stop these medications prior to procedures requiring anesthesia, but they should adhere to longer preoperative fasting times, according to a new multidisciplinary consensus statement.
-
6 days ago | 
medscape.com | Lucy Hicks
TOPLINE:An oral therapy targeting toll-like receptors (TLR) 7 and 8 reduced disease activity in patients with cutaneous lupus erythematosus (CLE) or systemic lupus erythematosus (SLE) with active lupus rash. METHODOLOGY:Cohort A of the phase 2 WILLOW study included patients with CLE and patients with mild SLE and active skin manifestation for whom no approved treatments currently exist.
-
1 month ago | 
medscape.com | Lucy Hicks
All tumor necrosis factor (TNF) inhibitors are safe to use throughout pregnancy, according to new recommendations from the European Alliance of Associations for Rheumatology (EULAR). All biologic disease-modifying antirheumatic drugs (bDMARDs) can also be continued while breastfeeding, and women should not be discouraged from breastfeeding while taking compatible medications.
-
1 month ago | 
medscape.com | Lucy Hicks
The US Food and Drug Administration (FDA) has approved a new indication for upadacitinib as a treatment for giant cell arthritis (GCA) in adults. This is the first oral JAK inhibitor indicated for GCA, according to the drug manufacturer AbbVie.
-
1 month ago | 
medscape.com | Lucy Hicks
A multidisciplinary team has released new evidence-based recommendations for the management of familial Mediterranean fever (FMF). Jointly endorsed by the European Alliance of Associations for Rheumatology (EULAR) and the Pediatric Rheumatology European Society, the recommendations are the first update to the 2016 EULAR guidelines. Although rare, FMF is the most common monogenic autoinflammatory disease and is most prevalent in people of Mediterranean or Middle Eastern descent.
-
2 months ago | 
medscape.com | Lucy Hicks
Biologics are more effective at treating adult-onset Still’s disease (AOSD) than glucocorticoids or conventional disease-modifying antirheumatic drugs (DMARDs), according to a new retrospective study. Half of the patients treated with first-line biologic DMARDs achieved sustained, event-free remission compared with 12% of patients in the conventional therapy group.
-
2 months ago | 
medscape.com | Lucy Hicks
The US Food and Drug Administration (FDA) has approved the B-cell depleting agent inebilizumab-cdon (Uplizna, Amgen) for the treatment of immunoglobulin G4-related disease (IgG4-RD). This is the first and only treatment approved for this rare autoimmune disease in the United States. An estimated 200,000 people in the United States are living with IgG4-RD, according to a press release from Amgen.
-
2 months ago | 
medscape.com | Lucy Hicks
Nearly 2 years after entering the market, adalimumab biosimilars are finally seeing traction. CVS Health’s Caremark, Cigna’s Express Scripts, and UnitedHealth Group’s OptumRx, which are pharmacy benefit managers (PBMs) that collectively control about 80% of all prescriptions in the United States, are now pivoting away from Humira and preferring biosimilars on their formularies.
-
2 months ago | 
medscape.com | Lucy Hicks
The US Food and Drug Administration (FDA) has approved denosumab-bnht (Conexxence/Bomyntra), manufactured by Fresenius Kabi, for all indications of the reference product denosumab (Prolia/Xgeva). The biosimilar will launch in the United States in June 2025 as part of a global settlement with Amgen, which manufactures the reference product.
